rekambys
janssen-cilag international nv - rilpivirine - hiv-infektionen - antivirale mittel zur systemischen anwendung - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.
rukobia
viiv healthcare b.v. - fostemsavir trometamol - hiv-infektionen - antivirale mittel zur systemischen anwendung - rukobia, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant hiv-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
sunlenca
gilead sciences ireland unlimited company - lenacapavir sodium - hiv-infektionen - antivirale mittel zur systemischen anwendung - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 und 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 und 5.
medivitan iv fertigspritze
medice arzneimittel pütter gmbh & co. kg - geschäftsanschrift - (3083819) - pyridoxinhydrochlorid; cyanocobalamin; folsäure-hydrat - injektionslösung - teil 1 - injektionslösung; pyridoxinhydrochlorid (00275) 5 milligramm; cyanocobalamin (00093) 1 milligramm; teil 2 - injektionslösung; folsäure-hydrat (00127) 1,05 milligramm
medivitan iv ampullen
medice arzneimittel pütter gmbh & co. kg - geschäftsanschrift - (3083819) - pyridoxinhydrochlorid; cyanocobalamin; folsäure-hydrat - injektionslösung - teil 1 - injektionslösung; pyridoxinhydrochlorid (00275) 5 milligramm; cyanocobalamin (00093) 1 milligramm; teil 2 - injektionslösung; folsäure-hydrat (00127) 1,05 milligramm
poulvac pabac iv
zoetis deutschland gmbh (4402304) - subkutane anwendung; subkutane anwendung; subkutane anwendung; pasteurella multocida, serotyp 1, stamm x-73, inaktiviert; pasteurella multocida, serotyp 3, stamm p-1059, inaktiviert; pasteurella multocida, serotyp 4, stamm p-1662, inaktiviert; pasteurella multocida, serotyp 3x4, stamm cu, inaktiviert - emulsion zur injektion - subkutane anwendung (ente) - -; subkutane anwendung (huhn) - -; subkutane anwendung (truthuhn) - -; pasteurella multocida, serotyp 1, stamm x-73, inaktiviert (35385) 70 prozent schutz; pasteurella multocida, serotyp 3, stamm p-1059, inaktiviert (35386) 70 prozent schutz; pasteurella multocida, serotyp 4, stamm p-1662, inaktiviert (35387) 70 prozent schutz; pasteurella multocida, serotyp 3x4, stamm cu, inaktiviert (35388) 70 prozent schutz - truthuhn; huhn; ente
rocephin iv 1g pulver und lösungsmittel zur herstellung einer injektionslösung
roche pharma ag (3001678) - ceftriaxon-dinatrium 3.5 h<2>o - pulver und lösungsmittel zur herstellung einer injektionslösung - ceftriaxon-dinatrium 3.5 h<2>o (22409) 1,193 gramm
rocephin iv 500mg pulver und lösungsmittel zur herstellung einer injektionslösung
roche pharma ag (3001678) - ceftriaxon-dinatrium 3.5 h<2>o - pulver und lösungsmittel zur herstellung einer injektionslösung - ceftriaxon-dinatrium 3.5 h<2>o (22409) 596,5 milligramm
purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.